Expanded Activated Lymphocytes (EAL) as Adjuvant Therapy in Patients With HCC at High Risk of Recurrence After Radical Resection

Chinese PLA General Hospital (301 Hospital)

Status and phase: Unknown; Phase 2

Conditions: Hepatocellular Carcinoma (HCC)

Treatments: Procedure: transarterial chemoembolization (TACE); Biological: Expanded Activated Lymphocytes (EAL)

Study type: Interventional

Funder types: Other; Industry

Identifiers

NCT05213637

EAL-HCC-001

Details and patient eligibility

About

This is a multi-center, randomized, open-label pivotal phase II study to evaluate the efficacy and safety of EAL as adjuvant therapy in preventing recurrence in patients with primary HCC at high recurrence risk after radical resection.

Full description

HCC, accounting for 80% of all liver cancers, is the third most common cause of cancer-related death worldwide. Radical resection is considered as a curative strategy for patients with primary HCC. However, over 50% of patients experience recurrence after resection, resulting in a very low 5-year survival rate. EAL are ex vivo expanded and activated lymphocytes comprising mainly CD8+ T cells derived from patients' peripheral blood. This is a multi-center, randomized, open-label pivotal phase II study to evaluate the efficacy and safety of EAL in preventing recurrence in patients with primary HCC at high recurrence risk after radical resection. Patients will be randomized in a 1:1 ratio to receive either 20 doses of EAL (1×10^9~2×10^10 per dose) infusion in combination of a single TACE or a single TACE only. Primary endpoint is the independent review committee-determined recurrence-free survival (from randomization to first recurrence or death from any cause). Secondary endpoints include overall survival, cancer-specific survival, adverse events and others.

Enrollment: 430 estimated patients

Sex: All

Ages: 18 to 75 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Patients with Stage Ia~IIIa primary HCC with high recurrence risk (defined as single tumor ≥5cm in diameter, or single tumor <5cm in diameter with MVI, PVTT, hepatic vein invasion, satellite lesions or AFP ≥400ng/mL, or multiple tumors).
2. Patients who have undergone a radical resection.
3. ECOG PS Score 0~2.
4. Child-Pugh Score ≤ 7.
5. Patients with adequate hematologic and end-organ function.
6. HBV-HCC and HCV-HCC patients with active viral infection may receive antiviral treatment simultaneously.
7. Patients who have a life expectancy of at least 6 months.

Exclusion criteria

1. Patients with a history of immune deficiency or autoimmune diseases (such as rheumatoid joint disease, systemic lupus erythematosus, vasculitis, multiple sclerosis, insulin-dependent diabetes mellitus, etc.).
2. Patients with a history of other malignant tumors in the past 5 years.
3. Patients who received chemotherapy, radiotherapy, molecular targeted therapy, biological immunotherapy, and hormone therapy within 1 month prior to screening.
4. Patients who have received microwave ablation, cryotherapy, high-power ultrasound focused ablation and other local ablation methods for liver tumors.
5. Patients with postoperative organ dysfunction or heart and lung diseases.
6. Patients allergic to albumin or with serious allergy history or mental disease.
7. Pregnant or lactating women.
8. Anticipated other clinical trials within 4 weeks before this trial.
9. Patients with HIV or Treponema pallidum infection, septicemia and other uncontrolled infection.
10. Patients after organ or bone marrow transplant.
11. Patients with drug or alcohol abuse/addiction.
12. Any condition that would, in the investigator's judgment, make it unsuitable for the donors to be enrolled.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

430 participants in 2 patient groups

EAL Treatment Group

Experimental group

Description:

The patients with primary HCC will receive 12\~20 doses of EAL infusion (1×10\^9\~2×10\^10 cells per dose) in combination of a single transarterial chemoembolization (TACE) after radical resection.

Treatment:

Biological: Expanded Activated Lymphocytes (EAL)

Procedure: transarterial chemoembolization (TACE)

Control Group

Active Comparator group

Description:

The patients with primary HCC will receive a single TACE after radical resection.

Treatment:

Procedure: transarterial chemoembolization (TACE)